India’s Human Trial of Covaxin (BBV152) to Start at Bhubaneswar from Tomorrow

The research for the Covid-19 vaccine has intensified in India with the coronavirus case reaching 11.5 lakh today. India will start clinical trials with the first Covid-19 vaccine Covaxin. In Phase 1, 375 people will be tested with the vaccine. 

From 22nd July, in Bhubaneswar, the human clinical trials of BBV152 COVID Vaccine (Covaxin) will be started. It is one of the 12 centres selected by the ICMR for conducting phase one and two of the clinical trials. 

India is the largest vaccine manufacturer in the world. Over 60% of the Drugs supplied to the world are from India. India is hence called the “pharmacy of the world”.

In phase 1 and 2 clinical trials, more than 1,100 individuals will receive tests of Covaxin, developed by Bharat BioTech in collaboration with ICMR and NIV, Pune.

Any healthy person willing to participate in this trial should send an email to Ctaiims.covid19@gmail.com or an SMS to 7428847499. The first and second phases of the AIIMS project (Delhi) are to pick only 100 of the 375 participants and the others to participate.